Observation versus initial treatment for men with localized, low-risk prostate cancer: A cost-effectiveness analysis

Annals of Internal Medicine

Volumn 158, Issue 12, 2013, Pages 853-860

  Hayes, Julia H ^a   Ollendorf, Daniel A ^b   Pearson, Steven D ^b   Barry, Michael J ^c   Kantoff, Philip W ^a   Lee, Pablo A ^d   McMahon, Pamela M ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Institute for Technology Assessment   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SURVEILLANCE; AGED; ARTICLE; BRACHYTHERAPY; CANCER RISK; CLINICAL OBSERVATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; WATCHFUL WAITING;

AGED; BIOPSY; BRACHYTHERAPY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIGITAL RECTAL EXAMINATION; DISEASE PROGRESSION; HEALTH CARE COSTS; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; WATCHFUL WAITING;

EID: 84879163282     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-158-12-201306180-00002     Document Type: Article

References (48)

1. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-9. [PMID: 19297565].
2. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer Register (NPCR) of Sweden. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010;102:950-8. [PMID: 20562373]
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8. [PMID: 19297566]
4. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202-9. [PMID: 19755699]
5. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007; 178:S14-9. [PMID: 17644125]
6. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010; 102:605-13. [PMID: 20413742]
7. Institute for Clinical and Economic Review. IMRT Final Appraisal-Full Report. 2007. Accessed at www.icer-review.org/index.php/imrt.html on 22 April 2013.
8. Institute for Clinical and Economic Review. Active Surveillance and Radical Prostatectomy Final Appraisal. 2009. Accessed at www.icer-review.org/index.php/as-rp.html on 22 April 2013.
9. Institute for Clinical and Economic Review. Final Appraisal Document: Brachytherapy and Proton Beam Therapy for Treatment of Clinically Localized, Low-Risk Prostate Cancer. 2009. Accessed at www.icer-review.org/index.php/bt-pbt.html on 22 April 2013.
10. Penson DF, Chan JM; Urologic Diseases in America Project. Prostate cancer. J Urol. 2007;177:2020-9. [PMID: 17509282]
11. Shteynshlyuger A, Andriole GL. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. J Urol. 2011;185:828-32. [PMID: 21239021]
12. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126-31. [PMID: 19917860]
13. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-13. [PMID: 22808955]
14. The ProtecT trial-Evaluating the effectiveness of treatment for clinically localised prostate cancer [clinical trial]. 2012. Accessed at www.controlled-trials.com/ISRCTN20141297 on 22 April 2013.
15. Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304:2373-80. [PMID: 21119084]
16. Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007;109:518-27. [PMID: 17186528]
17. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012;118:3512-8. [PMID: 22180322]
18. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996:425.
19. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821-7. [PMID: 15315996]
20. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multiinstitutional pooled analysis. J Urol. 2005;173:797-802. [PMID: 15711272]
21. Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol. 2003; 21:3318-27. [PMID: 12947068]
22. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112:2664-70. [PMID: 18433013]
23. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004;171:1520-4. [PMID: 15017211]
24. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:1103-11. [PMID: 22277570]
25. van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, et al. Short-term outcomes of the prospective multicentre "Prostate Cancer Research International: Active Surveillance" study. BJU Int. 2010;105:956-62. [PMID: 19817747]
26. van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol. 2008;54:1297-305. [PMID: 18342430]
27. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int. 2005; 95:956-60. [PMID: 15839912]
28. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007;178:2359-64. [PMID: 17936806]
29. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005;43:347-55. [PMID: 15778638]
30. Dale W, Basu A, Elstein A, Meltzer D. Predicting utility ratings for joint health States from single health States in prostate cancer: empirical testing of 3 alternative theories. Med Decis Making. 2008;28:102-12. [PMID: 18057188]
31. U.S. Bureau of Labor Statistics. Consumer Price Index Medical Care. Washington, DC: U.S. Bureau of Labor Statistics; 2013. Accessed at http://data.bls.gov/cgi-bin/surveymost?cu on 22 April 2013.
32. Centers for Medicare & Medicaid Services. Hospital Outpatient Prospective Payment System (OPPS). Washington, DC: U.S. Department of Health and Human Services; 2008.
33. U.S. Bureau of Labor Statistics. Household Data Table 3: Median usual weekly earnings of full-time wage and salary workers by age, race, Hispanic or Latino ethnicity, and sex, quarterly averages, not seasonally adjusted. Washington, DC: U.S. Bureau of Labor Statistics; 2013. Accessed at www.bls.gov/webapps /legacy/cpswktab3.htm on 22 April 2013.
34. Dahabreh IJ, Chung M, Balk EM, Yu WW, Mathew P, Lau J, et al. Active surveillance in men with localized prostate cancer: a systematic review. Ann Intern Med. 2012;156:582-90. [PMID: 22351515]
35. Corcoran AT, Peele PB, Benoit RM. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. Urology. 2010;76:703-7. [PMID: 20381846]
36. Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, et al. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res. 2012;18:5471-8. [PMID: 23008476]
37. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011;29:2795-800. [PMID: 21632511]
38. Sheridan TB, Carter HB, Wang W, Landis PB, Epstein JI. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol. 2008;179:901-4. [PMID: 18207195]
39. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008;180:1964-7. [PMID: 18801515]
40. Groot Koerkamp B, Hunink MG, Stijnen T, Hammitt JK, Kuntz KM, Weinstein MC. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making. 2007;27:101-11. [PMID: 17409361]
41. Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS. Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics. 2009;27:533-45. [PMID: 19663525]
42. Thomson PDR. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson Reuters; 2008.
43. Centers for Medicare & Medicaid Services. Clinical Laboratory & Physician Fee Schedule. Washington, DC: U.S. Department of Health and Human Services; 2008.
44. Centers for Medicare & Medicaid Services. Durable Medical Equipment, Prosthetics/Orthotics & Supplies Fee Schedule. Washington, DC: U.S. Department of Health and Human Services; 2008.
45. Yabroff KR, Davis WW, Lamont EB, Fahey A, Topor M, Brown ML, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007;99:14-23. [PMID: 17202109]
46. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol. 2001;166:856-60. [PMID: 11490233]
47. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003;139:161-8. [PMID: 12899583]
48. Andersson SO, Rashidkhani B, Karlberg L, Wolk A, Johansson JE. Prevalence of lower urinary tract symptoms in men aged 45-79 years: a populationbased study of 40000 Swedish men. BJU Int. 2004;94:327-31. [PMID: 15291861]